| Stereochemistry | ABSOLUTE |
| Molecular Formula | C45H76N2O15 |
| Molecular Weight | 885.0893 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 19 / 19 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@H]1[C@@H](CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]3O[C@H](C)[C@@H](O[C@H]4C[C@@](C)(O)[C@@H](O)[C@H](C)O4)[C@@H]([C@H]3O)N(C)C)OC(C)=O
InChI
InChIKey=ZPCCSZFPOXBNDL-ZSTSFXQOSA-N
InChI=1S/C45H76N2O15/c1-25-22-31(20-21-48)41(62-44-39(51)38(47(10)11)40(28(4)58-44)61-37-24-45(7,53)43(52)29(5)57-37)42(54-12)34(59-30(6)49)23-35(50)55-26(2)16-14-13-15-17-33(25)60-36-19-18-32(46(8)9)27(3)56-36/h13-15,17,21,25-29,31-34,36-44,51-53H,16,18-20,22-24H2,1-12H3/b14-13+,17-15+/t25-,26-,27-,28-,29+,31+,32+,33+,34-,36+,37+,38-,39-,40-,41+,42+,43+,44+,45-/m1/s1
| Molecular Formula | C45H76N2O15 |
| Molecular Weight | 885.0893 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 19 / 19 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Acetylspiramycin for spiramycin acetylated derivatives, belonging to 16 membered ring macrolide. It is suitable for sensitive Staphylococcus, Streptococcus and Streptococcus pneumoniae induced by mild to moderate infections, such as pharyngitis, tonsillitis, sinusitis, otitis media, periodontitis, acute bronchitis, chronic bronchitis, pneumonia, non-gonococcal urethritis, skin and soft tissue infection, can be used for the selection of drugs for cryptosporidiosis, or as a treatment for pregnancy women of toxoplasmosis. The mechanism for Acetylspiramycin combined with sensitive microbial 50S ribosomal subunit, RNA dependent inhibition of protein synthesis and bacteriostasis.
Approval Year
PubMed
Patents
Sample Use Guides
Adult dosage: a 0.2 ~ 0.3g, 4 times a day, for the first time double.
Pediatric dose each day according to the weight of 20 ~ 30 mg/kg, 4 times a day
Route of Administration:
Oral
Resident mouse peritoneal macrophages cultured with acetylspiramycin (ASPM) (25-100 micrograms/ml for 18 h) showed a 62-92% reduction in phagocytosis. This was due to decreases in both attachment and ingestion of SRBC and was additional to the detachment of some macrophages from the surface of the culture chamber. Morphologically the macrophages were vacuolated, with some nuclear condensation. When the cells were cultured for a further 48 h after removal of ASPM there was almost complete functional and morphological recovery.
